{
    "Clinical Trial ID": "NCT00323479",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Anastrozole 1 mg",
        "  Anastrozole 1 mg once daily"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole",
        "  WHO performance status 0, 1 or 2",
        "  Provision of written informed consent",
        "Exclusion Criteria:",
        "  Recurrence of breast cancer, inflammatory rheumatism",
        "  treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin",
        "  Diabetes treated by insulin",
        "  Severe renal or hepatic disease",
        "  Known hypersensitivity to anastrozole"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Participants With New Events of Arthralgia",
        "  [Not Specified]",
        "  Time frame: 12 months",
        "Results 1: ",
        "  Arm/Group Title: Anastrozole 1 mg",
        "  Arm/Group Description: Anastrozole 1 mg once daily",
        "  Overall Number of Participants Analyzed: 106",
        "  Measure Type: Number",
        "  Unit of Measure: Participants  37"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/110 (5.45%)",
        "  Sudden death unexplained 1/110 (0.91%)",
        "  General body pain 1/110 (0.91%)",
        "  Lymphangitis 1/110 (0.91%)",
        "  Femur fracture 1/110 (0.91%)",
        "  Parathyroid adenoma 1/110 (0.91%)",
        "  Depression worsened 1/110 (0.91%)",
        "  Calculus urinary bladder 1/110 (0.91%)",
        "  Pneumopathy 1/110 (0.91%)"
    ]
}